Logo

ACTU

Actuate Therapeutics Inc

ACTU

Actuate Therapeutics Inc • NASDAQ
$7.63 ▲ 10.58% (+0.73)
Market Cap $177.35 M
52w High $11.99
52w Low $5.47
Dividend Yield 0%
P/E 22.44
Volume 54.91K
Outstanding Shares 23.24M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $5.472M ▼ $-5.407M ▲ 0% $-0.25 ▲ $-5.402M ▲
Q2-2025 $0 $5.969M ▼ $-5.949M ▲ 0% $-0.3 ▲ $-5.944M ▲
Q1-2025 $0 $6.366M ▼ $-6.317M ▲ 0% $-0.32 ▲ $-6.312M ▲
Q4-2024 $0 $6.559M ▲ $-6.446M ▼ 0% $-0.6 ▼ $-6.323M ▼
Q3-2024 $0 $5.393M $-5.971M 0% $-0.55 $-5.967M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $16.925M ▲ $17.714M ▲ $6.778M ▼ $10.936M ▲
Q2-2025 $6.493M ▲ $6.969M ▲ $9.623M ▲ $-2.654M ▲
Q1-2025 $3.889M ▼ $4.483M ▼ $9.571M ▲ $-5.088M ▼
Q4-2024 $8.642M ▼ $9.318M ▼ $9.214M ▲ $104.186K ▼
Q3-2024 $13.523M $14.263M $8.904M $5.359M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.407M ▲ $-6.678M ▼ $0 $17.11M ▲ $10.432M ▲ $-6.678M ▼
Q2-2025 $-5.949M ▲ $-4.349M ▲ $0 $6.952M ▲ $2.603M ▲ $-4.349M ▲
Q1-2025 $-6.317M ▲ $-4.619M ▲ $0 $-133.477K ▼ $-4.752M ▲ $-4.619M ▲
Q4-2024 $-6.446M ▼ $-4.772M ▲ $0 $-109.412K ▼ $-4.882M ▼ $-4.772M ▲
Q3-2024 $-5.971M $-9.149M $0 $22.321M $13.172M $-9.149M

Five-Year Company Overview

Income Statement

Income Statement Actuate is a classic early‑stage biotech: it has no product revenue yet and has been running steady operating losses for several years. The scale of its expenses looks relatively modest, reflecting a focused pipeline rather than a broad, costly portfolio. Losses have been widening on a per‑share basis as the company funds clinical development, which is normal for a small clinical‑stage firm but means the business is entirely dependent on external capital for now. Profitability will hinge entirely on future trial success and eventual approvals, so the income statement today mainly reflects research spending rather than an operating business.

Balance Sheet

Balance Sheet The balance sheet is very thin, with only a small cash base and essentially no other meaningful assets, which underscores how early and lean the company is. There is no reported financial debt, which removes interest‑burden risk but also suggests the company will likely lean on equity or partnerships to fund itself. Equity moved from negative to roughly breakeven territory most recently, hinting at some recapitalization or restructuring, but overall capitalization remains fragile. In practical terms, the company’s financial cushion appears limited relative to the long timelines of oncology development.

Cash Flow

Cash Flow Cash flows show a consistent outflow from operations, driven by research and clinical activities, with almost no spending on fixed assets. Free cash flow is negative but relatively stable, indicating controlled but ongoing cash burn. With no inflows from product sales, sustainability of the cash profile depends on future financing, grants, or deals. This pattern is typical for a small biotech, but it leaves limited room for delays or major trial setbacks before new funding is needed.

Competitive Edge

Competitive Edge Competitively, Actuate is trying to carve out a niche around a novel cancer target, GSK‑3β, where it may have first‑mover advantages. Its lead drug, elraglusib, has orphan drug status in multiple indications and a long patent runway, which, if approved, could translate into meaningful protection from direct competition. The focus on difficult cancers like pancreatic cancer and soft tissue sarcoma targets areas with high unmet need, where regulators and clinicians are often receptive to new options. However, the company is small and up against much larger oncology players, so it will likely need strong data and possibly partners to secure a durable position.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of the story: elraglusib combines direct cancer‑killing effects, potential to overcome treatment resistance, and immune‑modulating properties, which makes it a versatile candidate for combinations. The company is also leaning into precision medicine, using biomarker signatures and machine learning to select patients more likely to respond, which can improve trial efficiency and outcomes. Development of both intravenous and oral forms gives flexibility in how the drug might be used in real‑world practice. That said, nearly all of the value rests on a single main asset, so R&D risk is highly concentrated in this one program and its upcoming pivotal trials.

Summary

Actuate Therapeutics is a very early, clinical‑stage oncology company: no revenue, a lean balance sheet, ongoing cash burn, and heavy reliance on future financing and clinical success. Its appeal rests almost entirely on the potential of its lead GSK‑3β inhibitor, elraglusib, which has shown encouraging mid‑stage data, orphan designations, and a differentiated scientific rationale. The company is trying to build a moat through patents, biomarker‑driven development, and combination strategies in hard‑to‑treat cancers, but faces the usual biotech risks around trial results, timelines, and funding. Overall, this is a high‑risk, high‑uncertainty profile typical of small oncology biotechs, where outcomes will be determined less by current financials and more by the next few years of clinical and regulatory milestones.

NEWS

September 22, 2025 · 8:45 AM UTC

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Read more

September 10, 2025 · 8:31 AM UTC

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Read more

September 9, 2025 · 4:07 PM UTC

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Read more